Damon Runyon News
View New Articles By
View New Articles By
John Mendelsohn, MD (Damon Runyon Grantee ’72-’74), President Emeritus of MD Anderson Cancer Center, Houston, shared the 2018 Tang Prize in Biopharmaceutical Science with former Damon Runyon Sponsors Tony Hunter, PhD, at the Salk Institute, La Jolla, and Brian J. Druker, MD, at the OHSU Knight Cancer Institute, Portland. Dr. Mendelsohn led the development of a novel targeted therapy: the anti-EGFR antibody cetuximab (Erbitux®). His efforts resulted in its approval by the FDA for the treatment of colon cancer and head/neck cancer.
Researchers have long been aware that several viruses have an innate ability to kill cancer cells. Dmitriy Zamarin, MD, PhD (Damon Runyon Fellow ’13-’16) and Jedd D.
Five Damon Runyon alumni are among the 19 individuals named Howard Hughes Medical Institute Investigators this week. These scientists were selected because they ask hard questions in uncharted territories of biology and have the potential to make breakthroughs that will benefit humanity. The appointment provides flexible funding of $8 million over a seven-year term for each scientist, enabling them to pursue provocative fundamental questions of critical importance to biomedical progress.
Benjamin L. Martin, PhD (Damon Runyon-Rachleff Innovator ’17 – ’20), Stony Brook University, New York, received a 2018 Pershing Square Sohn Prize for Young Investigators in Cancer Research. Recipients receive $200,000 per year for up to three years and opportunities to present their work to scientific and business audiences, helping to bridge the gap between the academic and business communities.
Maria Mihaylova, PhD (Former Damon Runyon Fellow ‘13-’16) of the Whitehead Institute and MIT’s Koch Institute, Cambridge, has found benefits of intermittent fasting beyond weight loss. The researchers discovered that fasting for 24 hours dramatically improves stem cells’ ability to regenerate in the intestines of aged and young mice. When an injury or infection occurs, stem cells are key to repairing damage. This finding may help patients who suffer from GI infections or cancer patients undergoing chemotherapy.
Two Damon Runyon alumni were elected to the National Academy of Sciences (the science “Hall of Fame”), one of the highest honors that can be earned by a U.S. scientist. Being elected into this prestigious group of scientists recognizes their distinguished and continuing achievements in biomedical research. This brings the total number of Damon Runyon scientists who are members of the National Academy of Sciences to 74.
Gavin Dunn, MD, PhD (Damon Runyon Clinical Investigator '17-'20), and colleagues at Washington University in St. Louis, are developing a way to detect brain tumor biomarkers through a simple blood test. Taking a biopsy of a brain tumor is a complicated and invasive surgical process. The new groundbreaking, proof-of-concept technique allows biomarkers from a brain tumor to pass through the tough blood-brain barrier into a patient's blood using noninvasive focused ultrasound and some tiny bubbles, potentially eliminating the need for a surgical biopsy.
Benjamin L. Martin, PhD (Damon Runyon-Rachleff Innovator ’17-’18) and David Q. Matus, PhD (Damon Runyon-Rachleff Innovator ’17-’18, Damon Runyon Fellow '07-'10) of Stony Brook University, Stony Brook, and colleagues, have developed new cell imaging technology that allows scientists investigating cancer and other diseases insights into how cells operate in real-time. This is the first time high-resolution, three-dimensional footage of the process has been visualized in action.
The most deadly process in cancer is metastasis, when tumor cells spread to distant organs. Key to preventing metastasis is understanding how these cells are able to move through the body. Carey K. Anders, MD (Damon Runyon Clinical Investigator ’12-’15) of the University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, is shedding light on this process using genetic “snapshots” of both the primary tumor and the tumor after it has spread.
Two new studies confirm that pediatric and adult cancers have different mechanisms driving the disease. These are the first large-scale genomic comparisons, combing through the genomes of more than 1,700 tumors, from over 20 different kinds of childhood cancers. Daniela S. Gerhard, PhD (Damon Runyon Fellow ’83-’85) of NCI, Bethesda, and Angela J. Waanders, MD, MPH (Dale F. Frey Breakthrough Scientist ’15-’17, Damon Runyon-Sohn Pediatric Cancer Fellow ‘12-‘15) of Chilidren’s Hospital of Philadelphia, Philadelphia, contributed to these studies.